Direct-to-Patient RTSM

Date Published:

Traditionally, the goal of clinical supply teams has been to ensure that study supplies are available for use at a clinical trial site. Today, recent trends in trial design, such as hybrid and decentralized models, have prompted the need to deliver investigational products directly to patients at their homes.

Signant’s RTSM solution enables direct-to-patient clinical supply deliveries, providing benefits to all study stakeholders:

  • Reduce burdens on patients and sites
  • Provide full traceability
  • Improve workflow efficiency

Learn more in our brochure.

Download Now